Point Prevalence Study of Multidrug-Resistant Organism Carriage by Healthcare Personnel
NCT01952158 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800
Last updated 2018-09-10
Summary
Acquisition and transmission of MDROs in healthcare facilities is a major patient safety problem, afflicting in particular the antibiotic-exposed and immunodeficient patient populations. MDRO-colonized patients require isolation to reduce the risk of transmission to other patients, and frequently develop infections from their colonizing organisms.
Most clinically relevant MDROs are carried in the gastrointestinal tract; thus perirectal cultures are frequently the surveillance method used to screen for these pathogens. Surveillance to identify MDRO colonization allows for anticipation and timely initiation of effective treatment of patients who develop infection.
The precise modes of transmission within hospitals are not known, but contamination of the hands of healthcare personnel, patient care equipment, and the healthcare environment are thought to play major roles in transmitting MDRO. Suboptimal hand hygiene can lead to transmission on the hands of staff to other patients or colonization of their own gastrointestinal tract. Few studies have investigated intestinal colonization of healthcare professionals. Transmission of bacteria by healthcare personnel is thought to occur primarily via contaminated hands; we wonder whether gastrointestinal carriage by healthcare personnel also plays a role in nosocomial spread.
This study will screen a self-referred convenience sample of 400 healthcare personnel who have contact with patients or patient culture specimens for fecal carriage of MDRO at one point in time. A control group of 400 NIH employees or contractors who do not have contact with patients or patient specimens will also be screened. Samples will be linked to questionnaires to assess the exposure of staff members to patients or culture specimens with known MDRO colonization or infection. We will use molecular typing techniques to link healthcare personnel isolates to patient or environmental isolates. Finally, the study will be conducted in such a way as to preserve to the greatest extent possible the anonymity of volunteers, using a system of alphanumeric identifiers and unmanned drop boxes for specimen collection.
Conditions
- Multidrug Resistance
Sponsors & Collaborators
-
National Institutes of Health Clinical Center (CC)
lead NIH
Principal Investigators
-
Brooke K Decker, M.D. · National Institutes of Health Clinical Center (CC)
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-09-13
- Primary Completion
- 2013-09-13
- Completion
- 2017-01-13
Countries
- United States
Study Locations
More Related Trials
-
The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
NCT00911235 ·Status: COMPLETED ·Phase: PHASE1
-
Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects
NCT01651325 ·Status: COMPLETED ·Phase: PHASE1
-
Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
NCT01686607 ·Status: COMPLETED
-
Screening Anti-Fungal Exposure in Intensive Care Units
NCT03136926 ·Status: UNKNOWN
-
Studies of Disorders With Increased Susceptibility to Fungal Infections
NCT01222741 ·Status: RECRUITING
-
Efflux Pump Mediated Azole Resistance in Candida Albicans
NCT03659162 ·Status: UNKNOWN
-
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
NCT00002325 ·Status: COMPLETED ·Phase: NA
-
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients
NCT03067350 ·Status: COMPLETED
-
Fungal Surveillance in Bangladesh
NCT06103331 ·Status: RECRUITING
-
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
NCT00003883 ·Status: COMPLETED ·Phase: PHASE3
-
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
NCT02734862 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
NCT04702464 ·Status: COMPLETED ·Phase: PHASE1
-
Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
NCT00002132 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants
NCT03135106 ·Status: COMPLETED ·Phase: PHASE1
-
Changing Patterns of Candida Infections in Urban Medical Centers
NCT00366223 ·Status: COMPLETED
-
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
NCT00003031 ·Status: COMPLETED ·Phase: PHASE3
-
Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients
NCT00841971 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients
NCT00002438 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants
NCT06345794 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
NCT03340597 ·Status: COMPLETED ·Phase: PHASE1
-
Prophylaxis With Caspofungin in High-Risk Liver Transplantation
NCT00333645 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations
NCT01307930 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge
NCT02111629 ·Status: COMPLETED ·Phase: PHASE3
-
Single Ascending Oral Dose Study of F901318
NCT02394483 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
NCT00002041 ·Status: COMPLETED ·Phase: NA